The global DPP IV inhibitors market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing prevalence of type 2 diabetes and obesity, which are major risk factors for type 2 diabetes. The DPP IV inhibitors market is also driven by the increasing number of people who are diagnosed with type 2 diabetes and obesity in emerging economies such as China and India.
The global DPP IV inhibitors market has been segmented on the basis of type, application, and region. On the basis of type, it has been segmented into sitagliptin, vildagliptin, saxagliptin, linagliptin; on the basis of application it has been segmented into hospital pharmacies and retail pharmacies; on the basis of region it has been segmented into North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China) Middle East & Africa (Saudi Arabia).
DPP-4 inhibitors are a class of drugs that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is an enzyme that breaks down the incretin hormones glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP). GLP1 and GIP are released by the intestines in response to food intake, and they stimulate insulin secretion from beta cells in the pancreas. DPP-4 inhibitors increase levels of GLP1 and GIP, which leads to increased insulin production.
Industry Growth Insights published a new data on “DPP IV Inhibitors (DPP-4 Inhibitors) Market”. The research report is titled “DPP IV Inhibitors (DPP-4 Inhibitors) Market research by Types (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Others), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Players/Companies AstraZeneca, Boehringer, Eli Lilly, Merck, Mitsubishi Tanabe Pharma, Novartis, Takeda”.
Scope Of The Report
Report Attributes
Report Details
Report Title
DPP IV Inhibitors (DPP-4 Inhibitors) Market Research Report
By Type
Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
AstraZeneca, Boehringer, Eli Lilly, Merck, Mitsubishi Tanabe Pharma, Novartis, Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Report Segments:
The global DPP IV Inhibitors (DPP-4 Inhibitors) market is segmented on the basis of:
Types
Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Boehringer
- Eli Lilly
- Merck
- Mitsubishi Tanabe Pharma
- Novartis
- Takeda
 Market Overview.svg)
Highlights of The DPP IV Inhibitors (DPP-4 Inhibitors) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the DPP IV Inhibitors (DPP-4 Inhibitors) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DPP-4 inhibitors are medications that block the activity of DPP-4, an enzyme that is responsible for breaking down a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that helps to lower the levels of cholesterol in the blood. By blocking the activity of DPP-4, these medications can help to reduce the risk of heart disease and stroke.
Some of the major companies in the dpp iv inhibitors (dpp-4 inhibitors) market are AstraZeneca, Boehringer, Eli Lilly, Merck, Mitsubishi Tanabe Pharma, Novartis, Takeda.
The dpp iv inhibitors (dpp-4 inhibitors) market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. DPP IV Inhibitors (DPP-4 Inhibitors) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. DPP IV Inhibitors (DPP-4 Inhibitors) Market - Supply Chain
4.5. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Forecast
4.5.1. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size (000 Units) and Y-o-Y Growth
4.5.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Absolute $ Opportunity
5. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
5.3.1. Sitagliptin
5.3.2. Vildagliptin
5.3.3. Saxagliptin
5.3.4. Linagliptin
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share Forecast, 2019-2026
9. North America DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
9.7.1. Sitagliptin
9.7.2. Vildagliptin
9.7.3. Saxagliptin
9.7.4. Linagliptin
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share Forecast, 2019-2026
10. Latin America DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
10.7.1. Sitagliptin
10.7.2. Vildagliptin
10.7.3. Saxagliptin
10.7.4. Linagliptin
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share Forecast, 2019-2026
11. Europe DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
1.7.1. Sitagliptin
11.7.2. Vildagliptin
11.7.3. Saxagliptin
11.7.4. Linagliptin
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share, 2019-2026
12. Asia Pacific DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
12.7.1. Sitagliptin
12.7.2. Vildagliptin
12.7.3. Saxagliptin
12.7.4. Linagliptin
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share, 2019-2026
13. Middle East & Africa DPP IV Inhibitors (DPP-4 Inhibitors) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa DPP IV Inhibitors (DPP-4 Inhibitors) Market Size and Volume Forecast by Type
13.7.1. Sitagliptin
13.7.2. Vildagliptin
13.7.3. Saxagliptin
13.7.4. Linagliptin
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa DPP IV Inhibitors (DPP-4 Inhibitors) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global DPP IV Inhibitors (DPP-4 Inhibitors) Market: Market Share Analysis
14.2. DPP IV Inhibitors (DPP-4 Inhibitors) Distributors and Customers
14.3. DPP IV Inhibitors (DPP-4 Inhibitors) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Boehringer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mitsubishi Tanabe Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Takeda
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
